A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors
MD Anderson Study Status
This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with EGFR or HER2 exon 20 mutation that is stage IV or has come back. Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Information and next steps
EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Thoracic Head and Neck Medical
For general questions about clinical trials: